AKR1C3 Inhibitory Potency of Naturally-occurring Amaryllidaceae Alkaloids of Different Structural Types

被引:0
|
作者
Hulcova, Daniela [1 ]
Breiterova, Katerina [1 ]
Zemanova, Lucie [2 ]
Siatka, Tomas [3 ]
Safratova, Marcela [1 ,3 ]
Vaneckova, Nina [1 ]
Host'alkova, Anna [1 ]
Wsol, Vladimir [2 ]
Cahlikova, Lucie [1 ]
机构
[1] Charles Univ Prague, Fac Pharm, ADINACO Res Grp, Dept Pharmaceut Bot & Ecol, Heyrovskeho 1203, Hradec Kralove 50005, Czech Republic
[2] Charles Univ Prague, Fac Pharm, Dept Biochem Sci, Heyrovskeho 1203, Hradec Kralove 50005, Czech Republic
[3] Charles Univ Prague, Fac Pharm, Dept Pharmacognosy, Heyrovskeho 1203, Hradec Kralove 50005, Czech Republic
关键词
Amaryllidaceae alkaloids; Aldo-keto reductase 1C3; Tazettine; PROSTATE-CANCER; CELLS; ACETYLCHOLINESTERASE; APOPTOSIS; BUTYRYLCHOLINESTERASE; GROWTH;
D O I
暂无
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Aldo-keto reductase 1C3 (AKR1C3) is an important human enzyme that participates in the reduction of steroids and prostaglandins, which leads to proliferative signaling. AKR1C3 is frequently upregulated in various cancers, and this enzyme has been suggested as a therapeutic target for the treatment of these pathological conditions. The fact that the isoquinoline alkaloid stylopine has been identified as a potent AKR1C3 inhibitor has prompted us to screen a library of diverse types of Amaryllidaceae alkaloids, which biogenetically are isoquinoline alkaloids, on a recombinant form of AKRIC3. From the tested compounds, only tazettine showed moderate AKR1C3 inhibitory potency with an IC50 value of 15.8 +/- 1.2 mu M. Tazettine is a common Amaryllidaceae alkaloid, which could be used as a model substance for the further development of either analogues or related compounds with better inhibition potency.
引用
收藏
页码:245 / 246
页数:2
相关论文
共 6 条
  • [1] Cytotoxicity of Naturally Occurring Isoquinoline Alkaloids of Different Structural Types
    Chlebek, Jakub
    Doskocil, Ivo
    Hulcova, Daniela
    Breiterova, Katefina
    Safratova, Marcela
    Havelek, Radim
    Habartova, Klara
    Host'alkova, Anna
    Volstatova, Tereza
    Cahlikova, Lucie
    NATURAL PRODUCT COMMUNICATIONS, 2016, 11 (06) : 753 - 756
  • [2] Isoquinoline alkaloids as a novel type of AKR1C3 inhibitors
    Skarydova, Lucie
    Hofman, Jakub
    Chlebek, Jakub
    Havrankova, Jana
    Kosanova, Katerina
    Skarka, Adam
    Hostalkova, Anna
    Plucha, Tomas
    Cahlikova, Lucie
    Wsol, Vladimir
    JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2014, 143 : 250 - 258
  • [3] In vitro CAPE inhibitory activity towards human AKR1C3 and the molecular basis
    Li, Cuiyun
    Zhao, Yining
    Zheng, Xuehua
    Zhang, Hong
    Zhang, Liping
    Chen, Yunyun
    Li, Qing
    Hu, Xiaopeng
    CHEMICO-BIOLOGICAL INTERACTIONS, 2016, 253 : 60 - 65
  • [4] Inhibitory Interplay of SULT2B1b Sulfotransferase with AKR1C3 Aldo-keto Reductase in Prostate Cancer
    Park, Sulgi
    Song, Chung-Seog
    Lin, Chun-Lin
    Jiang, Shoulei
    Osmulski, Pawel A.
    Wang, Chiou-Miin
    Marck, Brett T.
    Matsumoto, Alvin M.
    Morrissey, Colm
    Gaczynska, Maria E.
    Chen, Yidong
    Mostaghel, Elahe A.
    Chatterjee, Bandana
    ENDOCRINOLOGY, 2020, 161 (02)
  • [5] Inhibitors of type 5 17β-hydroxysteroid dehydrogenase (AKR1C3): Overview and structural insights
    Byrns, Michael C.
    Jin, Yi
    Penning, Trevor M.
    JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2011, 125 (1-2): : 95 - 104
  • [6] Dual Inhibitory Action of a Novel AKR1C3 Inhibitor on Both Full-Length AR and the Variant AR-V7 in Enzalutamide Resistant Metastatic Castration Resistant Prostate Cancer
    Kafka, Mona
    Mayr, Fabian
    Temml, Veronika
    Moeller, Gabriele
    Adamski, Jerzy
    Hofer, Julia
    Schwaiger, Stefan
    Heidegger, Isabel
    Matuszczak, Barbara
    Schuster, Daniela
    Klocker, Helmut
    Bektic, Jasmin
    Stuppner, Hermann
    Eder, Iris E.
    CANCERS, 2020, 12 (08) : 1 - 18